About
Tactiva Therapeutics develops next-generation adaptive cell therapies (ACT) using a T-cell receptor (TCR) approach that combines CD4 and CD8 systems. Its autologous DEACT program targets NY-ESO-1 in ovarian and other solid tumors and has received IND clearance in the US.
Explore Tactiva Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.